Pharmaceuticals, Healthcare, and Innovation by Eli Lilly

Eli Lilly reported new clinical trial results showing its oral GLP-1 provided superior A1C control and weight loss. The results cover three clinical trials.Eli Lilly directed readers to its ...

Eli Lilly said women at every stage of menopause saw meaningful weight loss in post-hoc analyses of two studies of one of its obesity medicines, according to results presented at #ADA2026.The ...

Eli Lilly said adults with type 2 diabetes on its investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial.Eli Lilly presented results today at ...

Eli Lilly reported that its investigational triple agonist achieved a 73% reduction in knee osteoarthritis pain at the 12 mg dose in the TRIUMPH-1 study.The same drug reduced moderate-to-severe ...

Eli Lilly said its investigational triple agonist met all primary endpoints in the TRIUMPH-1 Phase 3 trial at ADA 2026.Patients on the 12 mg dose lost an average of 70 pounds, or 28.3%, over 80 ...

Eli Lilly said the future of obesity treatment will require medicines tailored to individuals at different stages of their treatment journeys.Rachel Batterham shared views on the need for ...

Eli Lilly announced its Community Skin Health Initiative and Sides of My Skin program to promote conversations about skin conditions within communities.The company said these efforts are based on ...

Eli Lilly reported new data at AAD2026 showing an approved treatment delivered durable disease control for up to four years in people with moderate-to-severe atopic dermatitis.The company said ...

Eli Lilly said one of its next-generation investigational incretin medicines delivered superior blood sugar control and weight loss compared to placebo in a late-stage clinical trial in people ...

​Eli Lilly is trading at around $917 per share after retracing from the $1,000 mark it had been testing recently. However, the company's pipeline for obesity treatment, diabetes management, and ...

Eli Lilly and Company has unveiled new data showing that children suffering from moderate-to-severe atopic dermatitis may achieve near-complete skin clearance and marked itch relief. The findings ...

Eli Lilly and Company has identified a potentially dangerous impurity in mass-produced counterfeit versions of its diabetes and obesity medicines. The contaminated products were compounded with ...

Eli Lilly and Company reports that its investigational GLP-1 pill demonstrated superior blood sugar control and weight loss compared to another GLP-1 therapy in a head-to-head trial for type 2 ...

Eli Lilly and Company has announced a significant $3 billion investment in a new manufacturing site in Katwijk, Netherlands. This move aims to enhance global access to oral medicines, building ...